©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 16037-16052
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16037
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16037
Table 2 Factors to differentiate severe acute exacerbation of chronic hepatitis B from acute hepatitis B
| Parameters | AVH-B | HBV-R | |
| IgM anti-HBc | > 600 Paul Ehrlich units/mL | Yes | Yes |
| (7 s and 8 s forms) | (19 s form) | ||
| > 1:1000 titer | Yes | No | |
| HBV DNA | > 2.25 × 104/mL | No | Yes |
| (121 000 copies/mL) | |||
| Liver biopsy: evidence of chronic hepatitis such as lymphocytic portal inflammation with interface hepatitis, spotty lobular inflammation, portal expansion, periportal fibrous strands, bridging fibrosis, and/or cirrhosis | No | Yes | |
| Basal core promoter mutation | No | Yes | |
| Pre-core stop codon mutation | No | Yes | |
- Citation: Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol 2014; 20(43): 16037-16052
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16037.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16037